Results 1 to 10 of about 9,498 (160)

The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis [PDF]

Medicina
Background and Objectives: Hepatitis C virus (HCV) infection is highly prevalent among patients undergoing chronic hemodialysis in emerging countries and is associated with significant morbidity and mortality in this population.
Sidi Mohamed Mah, Soufiane Sid’Ahmed, Mohamed Lemrabott, Delahi Welli, Jemal Awa, Abdellatif Sidi Aly, Lionel Rostaing   +6 more
doaj   +2 more sources

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior ...
Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung Woon Paik, Hyung Joon Kim, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, In Hee Kim, Sang Hoon Ahn, Young-Suk Lim   +24 more
doaj   +1 more source

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis [PDF]

Clinical and Molecular Hepatology, 2021
Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis.
Po-Yao Hsu, Yu-Ju Wei, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Shang-Jyh Hwang, Wan-Long Chuang, Chung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu   +23 more
doaj   +1 more source

Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line

Anais da Academia Brasileira de Ciências, 2021
Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C. Sofosbuvir and simeprevir are prescribed worldwide. However, there is a scarcity of information regarding their genotoxicity.
CARINA S. LIBRELOTTO, ANA PAULA DE SOUZA, MÁRIO R. ÁLVARES-DA-SILVA, DANIEL SIMON, RAFAEL R. DIHL   +4 more
doaj   +1 more source

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2023
Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Mohammad Ashraf Bhat, Aadil Nabi Mir, Manzoor Ahmad Parry, Irshad Ahmad Parray   +3 more
doaj   +1 more source

Sofosbuvir [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Cong, Jasen, Baker, Danial E   +2 more
openaire   +3 more sources

Ledipasvir/Sofosbuvir [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Danial E, Baker, Ross Jason, Bindler   +2 more
openaire   +2 more sources

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BMC Gastroenterology, 2020
Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C   +14 more
doaj   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

Український Журнал Нефрології та Діалізу, 2020
Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to ...
M. Mostafi, M. Jabin, Z. Chowdhury, M.U. Khondoker, S.M. Ali, R. Tamanna, R. Rezwan, S.B. Alomgir   +7 more
doaj   +1 more source